Ann: Imugene Dose Escalates in PD1-VAXX Phase 1 Clinical Trial, page-33

DappaT, it may or may not. But the market reaction is typically since I started investing into IMU in 2016. Great news get announced, hardly any positive market reaction.

1. Aussies don't give a damn about that:

" The CRC unanimously agreed PD1-Vaxx to be safe with no dose-limitiing toxicities (DLTs) and no
serious adverse reactions observed after CRC review of all safety and tolerability data for the first 3
patients dosed with lowest dose of PD1-Vaxx (10mcg) as monotherapy. "

"cause they think that's a given. No, it is not. It is an "IMU - given", but not in general.


2. That's what is at stake here:

" Clinicians at study sites in Australia and USA will also determine if the administration of PD1-Vaxx as
a monotherapy in patients who have progressed on standard of care immune checkpoint inhibitors
will prolong survival, delay tumor progression, or reduce the tumor burden in patients with lung cancer. "

And between the lines LC said, it works.

" “We are pleased with the results that we have seen so far
with no observed toxicity. Everyone supporting the study who are involved in developing this
important new cancer therapy are very encouraged by the progress to date. "

Wouldn't be surprised at all to see the sp getting pushed back to 10.5c by end of day. They throw their money at bubble - stocks and ignore the real deals.
But we all know that at least big pharma knows how to value success. The huge sp rise will come overnight, from 10.5c to $1 when t/o or multi billion $ deals are announced.

GLTA